Malcolm Ranson et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 25(18), 2540-2545 (2007-06-20)
To evaluate tumor response, pharmacodynamic effects, and safety of a combination of lomeguatrib (LM), an O6-methylguanine DNA-methyltransferase (MGMT) inactivator, and temozolomide (TMZ), TMZ alone, and LM/TMZ after disease progression on TMZ alone in patients with advanced melanoma. Patients with unresectable...
[Analysis of the relevant factors of mechanism for telozolomide chemoresistance].
Zeng-feng Sun et al.
Zhonghua zhong liu za zhi [Chinese journal of oncology], 33(10), 794-796 (2012-02-18)
T Brian H McMurry
DNA repair, 6(8), 1161-1169 (2007-05-09)
The DNA repair protein, O(6)-alkylguanine-DNA alkyltransferase (MGMT) can confer resistance to the cancer chemotherapeutic effects of the class of DNA damaging drugs generally referred to as the O(6)-alkylating agents. Inactivation of MGMT is thus a practical approach to improving the...
O A Khan et al.
British journal of cancer, 98(10), 1614-1618 (2008-05-14)
To evaluate the tumour response to lomeguatrib and temozolomide (TMZ) administered for 5 consecutive days every 4 weeks in patients with metastatic colorectal carcinoma. Patients with stage IV metastatic colorectal carcinoma received lomeguatrib (40 mg) and TMZ (50-200 mg m(-2))...
A Sabharwal et al.
Cancer chemotherapy and pharmacology, 66(5), 829-835 (2009-12-30)
Expression of the DNA repair protein O (6)-methylguanine-DNA methyltransferase (MGMT) correlates with resistance to irinotecan in colorectal cancer cell lines. This phase I study evaluated the maximum tolerated dose (MTD) of lomeguatrib, an inactivating pseudosubstrate of MGMT, in combination with...